全反式花生四烯酸甲酯 | 38575-18-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 全反式花生四烯酸甲酯
• 英文名称: arachidonic acid methyl ester
• 英文别名: 5,8,11,14-Eicosatetraenoic acid, methyl ester；methyl (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate
• CAS: 38575-18-7
• 化学式: C₂₁H₃₄O₂
• 分子量: 318.5
• InChiKey: OFIDNKMQBYGNIW-SHDWVJIKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  23
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  全反式花生四烯酸甲酯 在 氢氧化钾 、 乙醇 作用下， 生成 花生四烯酸
  参考文献：
  名称：

  Brown, Journal of Biological Chemistry, 1928, vol. 80, p. 458

  摘要：

  DOI：
• 作为产物：
  描述：

  花生四烯酸 在 异丙醇 、 2-巯基乙醇 作用下， 生成 全反式花生四烯酸甲酯
  参考文献：
  名称：

  Synthesis of all-trans arachidonic acid and its effect on rabbit platelet aggregation

  摘要：

  A simple and high-yielding method to convert natural all-cis PUFA derivatives to the corresponding all-trans geometrical isomers is described. The method is based on the thiyl radical-catalyzed cis-trans isomerization. The all-trans isomer of arachidonic acid was found to cause rabbit platelet aggregation at concentrations higher than 0.1 mM and inhibition of PAF-induced platelet aggregation in a concentration dependent manner with an IC50 in the micromolar range. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.109

文献信息

• [EN] PKC ACTIVATORS AND COMBINATIONS THEREOF<br/>[FR] ACTIVATEURS DE PKC ET DES COMBINAISONS DE CEUX-CI
  申请人：BRNI NEUROSCIENCES INST

  公开号：WO2013071282A1

  公开（公告）日：2013-05-16

  The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.

  本公开涉及PKC激活剂及其组合物。本公开进一步涉及其组成物、试剂盒、用途和方法。
• PKC activators and combinations thereof
  申请人：Cognitive Research Enterprises, Inc.

  公开号：US10821079B2

  公开（公告）日：2020-11-03

  The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.

  本公开涉及PKC激活剂及其组合物。该公开进一步涉及这些组合物的组成、试剂盒、用途和方法。
• Inhibitors of fatty acid amide hydrolase
  申请人：Boger L Dale

  公开号：US20060111359A1

  公开（公告）日：2006-05-25

  Improved competitive inhibitors of FAAH employ an α-keto heterocyclic pharmacophore and a binding subunit having a ?-unsaturation. The α-keto heterocyclic pharmacophore and a binding subunit are attached to one another, preferably by a hydrocarbon chain. The improvement lies in the use of a heterocyclic pharmacophore selected from oxazoles, oxadiazoles, thiazoles, and thiadiazoles that have alkyl or aryl substituents at their 4 and/or 5 positions. The improved competitive inhibitors of FAAH display enhanced activity over conventional competitive inhibitors of FAAH.

  改进的FAAH竞争性抑制剂采用α-酮杂环药基和具有?-不饱和度的结合亚单位。α-酮杂环药基和结合亚单位相互连接，最好通过一个碳氢链。改进之处在于使用从噁唑、噁二唑、噻唑和噻二唑中选择的具有烷基或芳基取代基的杂环药基，其在其4和/或5位置。改进的FAAH竞争性抑制剂显示出比传统FAAH竞争性抑制剂更强的活性。
• Process for producing powdered compositions containing highly unsaturated fatty acid esters of ascorbic acid and powdered compositions containing the esters
  申请人：Fukami Harukazu

  公开号：US20060160891A1

  公开（公告）日：2006-07-20

  The invention provides a process for powdering highly unsaturated fatty acid esters of ascorbic acid which are pasty and problematic in physical properties by a simple and easy means; highly unsaturated fatty acid esters of ascorbic acid which are improved in stability by powdering; and compositions containing the powdered highly unsaturated fatty acid esters of ascorbic acid. Specifically, a process for powdering a highly unsaturated fatty acid ester of ascorbic acid as represented by the general formula (I): RCO-A [wherein RCO— is acyl derived from a highly unsaturated fatty acid; and A is an ascorbic acid residue bonded through an —O— linkage resulting from an hydroxyl group of ascorbic acid], characterized by mixing a highly unsaturated fatty acid ester of ascorbic acid as represented by the general formula (I) with an aqueous solution of a water-soluble filler to form an emulsion and dehydrating and drying the emulsion by a spray drying method

  该发明提供了一种用简单易行的方法对抗坚固、物理性能有问题的抗坚固脂肪酸酯粉化的过程；通过粉化改善稳定性的抗坚固脂肪酸酯抗坚固酸；以及含有粉化的抗坚固脂肪酸酯抗坚固酸的组合物。具体来说，一种抗坚固脂肪酸酯抗坚固酸的粉化过程，其表示为通式(I)：RCO-A [其中RCO—是由抗坚固脂肪酸衍生的酰基；A是由抗坚固酸的羟基形成的—O—键连接的抗坚固酸残基]，其特征在于将抗坚固脂肪酸酯抗坚固酸按通式(I)表示的抗坚固脂肪酸酯抗坚固酸与水溶性填料的水溶液混合形成乳状液，并通过喷雾干燥方法脱水和干燥乳状液。
• [EN] HETEROCYCLIC COMPOUNDS AS LIPOXYGENASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS COMME INHIBITEURS DE LIPOXYGÉNASES
  申请人：DR REDDYS INST OF LIFE SCIENCES

  公开号：WO2020255156A1

  公开（公告）日：2020-12-24

  The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein X, R1, R2, R3, R4, R5, R6, m and n are as defined in the detailed description. The present invention also relates to pharmaceutical compositions containing one or more compounds of the formula (I), as well as methods of treating or preventing diseases and/or disorders mediated by aberrant or undesired expression of one or more lipoxygenases (LOXs) using such compounds or compositions.

  本发明涉及一种化合物，其化学式为（I）：或其药用可接受的盐或立体异构体，其中X、R1、R2、R3、R4、R5、R6、m和n的定义如详细描述中所述。本发明还涉及含有一种或多种化合物的药物组合物（I）的制备方法，以及使用这些化合物或组合物治疗或预防由一种或多种脂氧化酶（LOXs）异常或不良表达介导的疾病和/或疾病的方法。